Apixaban
Hypertension, Portal
Asian Institute Of Medical SciencesSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the Hypertension, Portal cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CARVEDILOL West China Hospital | Phase 4 | BBB |
SIMVASTATIN Kafrelsheikh University | Phase 4 | BBB |
PROPRANOLOL West China Hospital | Phase 4 | BBB |
LACTULOSE University of Michigan | Phase 4 | BB |
Dipyridamole Northern Jiangsu People's Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Apixaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →